FDA Hears 80 Speakers on Psychedelic Drug Therapy Standards

CONFERENCE COVERAGE | Considerations for Potential Future Therapeutic Use of Psychedelic Drugs FDA Public Hearing

The FDA convened a public hearing on the therapeutic use of psychedelic drugs, drawing more than 1,800 registered attendees and 80 scheduled speakers. The event, held in collaboration with NIDA, SAMHSA, the Veterans Health Administration, and ARPA-H, focused on four topic areas: provider training and credentialing, patient safety, access, and data standardization. Opening remarks were delivered by Dr. Marta Sokolowska, Deputy Center Director for Substance Abuse and Behavioral Health at FDA’s Center for Drug Evaluation and Research. Newly installed CDER Director Dr. Michael Davis attended the afternoon session.

A Field Growing Faster Than Its Framework

The hearing came at a pivotal regulatory moment. In April 2026, FDA issued national priority vouchers to three companies studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for PTSD. The agency also allowed an early-phase trial of noribogaine chloride for alcohol use disorder to proceed under an IND. In July 2026, FDA finalized guidance on clinical investigations for psychedelic drugs and published a commentary in the New England Journal of Medicine outlining its new regulatory framework.

FDA received more than 200 speaker requests by the August deadline, more than double the available slots. Speakers were randomly selected with attention to topic coverage and organizational diversity. The public docket remains open through October 5, 2026.

One recurring theme: the treatment gap is already generating real-world harm. Multiple speakers, including veterans and a combat-wounded nurse practitioner, described traveling outside the United States, to Mexico and other countries, to access ibogaine and ayahuasca because domestic options did not exist. One Iraq War veteran described years of underground practice to keep fellow veterans from dying by suicide. A retired Green Beret said ketamine therapy was “like a reset button” after half a dozen psychiatric medications failed him, and described nearly needing crisis intervention himself before finding treatment.

Credentialing: Competency Over Credentials

The most contested topic was who should be allowed in the treatment room, and what qualifications they need. Opinions ranged sharply.

A psychiatrist at Sheppard Pratt who has cared for roughly 200 participants across more than 10 psychedelic trials argued that psychiatrists should be required to lead psychedelic treatment, warning that commercial pressures could sideline psychiatric expertise behind a veneer of clinical legitimacy. By contrast, a Columbia University professor argued against novel licensing layers, contending that psychedelic treatment should stay within mainstream behavioral health scope of practice to prevent patients from being diverted to less regulated settings.

A licensed clinical social worker and practice founder pushed for explicit credentialing of preparation and integration competencies, distinct from in-session monitoring, and called for ongoing clinical consultation requirements throughout a practitioner’s career. A founder of the nation’s first accredited psilocybin facilitator training program cited a JAMA Network Open multi-site study of 346 Oregon patients in which four experienced serious adverse events; only one was identified during the session, with the other three surfacing weeks later through follow-up, an argument for longitudinal safety monitoring, not just session oversight.

Multiple speakers called for competency-based assessment rather than hourly training requirements. A simulation platform founder noted that hours are easy to satisfy and hard to verify, while demonstrated competency can be audited. Representatives from nursing, pharmacy, and occupational medicine each argued their professions were underrepresented in current guidance. The American Pharmacists Association formally requested that pharmacists be recognized as essential members of the psychedelic care team, citing existing infrastructure for controlled substance storage, inventory, and compliance.

Australia’s experience drew direct comparison. A representative of a publicly traded Australian company reported conducting more than 500 dosing sessions since October 2023 under that country’s authorized prescriber scheme, with no severe adverse reactions and with coverage from Australia’s largest private insurer and its veterans affairs department. The company treats patients excluded from clinical trials, including those with elevated blood pressure and personality disorders, a population that panelists noted represents the real-world caseload more accurately than trial enrollees.

Access: Geography, Cost, and the Insurance Gap

Access concerns dominated the afternoon session. A Nevada veterans coalition leader noted that nearly 87% of Nevadans live in a federally designated mental health professional shortage area, and that the FDA’s July guidance recommendation, that a physician be reachable within 15 minutes when a non-physician serves as lead monitor, would effectively disqualify every clinic in rural and frontier Nevada. He urged the agency to allow product-specific emergency protocols combining on-site personnel, remote physician consultation, and EMS activation.

A founder of one of the country’s largest brain medicine networks, operating TMS and ketamine across 27 clinics in seven states, offered a cautionary data point: esketamine was approved in 2019, but sales were so small for the first two years that they were not separately reported. It took five years to reach scale. The science did not change, infrastructure did. The speaker made three specific requests: write labels with payers in mind so that undefined terms cannot become denial criteria; standardize adverse event capture and outcome measures before launch; and work with CMS on permanent CPT codes that reflect the full cost of a trained team in a room for a full day.

A documentary filmmaker who spent eight years filming psychedelic therapy training reported that the clinics most likely to close were not shut down by adverse events, they closed because patients could not pay. He filmed a low-income clinic in Oregon and a ketamine clinic in Lubbock, Texas, both of which failed not due to safety failures but due to reimbursement gaps, leaving patients mid-treatment with no follow-up.

Speakers also raised women’s health as an underserved area. One advocacy founder cited National Academies data showing that from 2013 to 2023, just 8.8% of NIH research grant funding went to women’s health research. A clinical pharmacist noted that menstrual cycle phase, pregnancy, postpartum status, perimenopause, and menopause all alter neurobiology and pharmacology, yet these variables are routinely excluded from psychedelic trials or treated as confounders.

Not all speakers supported accelerated access. One former ONDCP advisor cited rising hallucinogen-related emergency department visits, a Canadian study linking hallucinogen ER visits to 3.5 times greater likelihood of developing schizophrenia, and an 8-fold increase in psilocybin poison control cases among children under 12 over five years. He urged the FDA to require full scientific approval before expanding access and warned against allowing advocacy pressure to substitute for rigorous trial evidence.

Data: Build the Infrastructure Now or Pay Later

Multiple speakers argued that the window to establish common data elements is closing, and that waiting until registries are built will make meaningful comparison impossible.

A Johns Hopkins postdoctoral researcher presented a meta-analysis from his lab, published in JAMA Psychiatry, finding that roughly 4% of psychedelic trial participants with pre-existing psychiatric conditions encountered serious adverse events even with intensive oversight and restrictive screening. He recommended anchoring initial post-approval safeguards closely to trial conditions, with pre-specified review points and defined evidentiary thresholds for relaxing or tightening requirements.

A regulatory consultant specializing in ibogaine warned that no validated cardiac prediction model currently exists for ibogaine despite documented QTc prolongation and ventricular arrhythmia at therapeutic doses. She called for a minimum common data element set, including metabolizer status, time-matched ECG, drug dose, and indication, to be published before registry infrastructure is built, arguing that a registry without common data elements produces volume, not evidence.

A UC Berkeley research physician called for a standardized glossary of psychedelic adverse events, noting that FDA guidance requires investigators to document all central nervous system effects as adverse events regardless of valence. Without common definitions, she argued, trial safety data reflects each team’s interpretation rather than the drug’s actual risk profile. Her team is developing a glossary in collaboration with UCSF and invited FDA to participate.

A Puerto Rico researcher flagged a structural gap: the National Survey on Drug Use and Health, the primary source for national psilocybin prevalence estimates, has no territorial sample frame, meaning approximately 3.2 million American citizens are excluded from the baseline data underpinning regulatory decisions. He called for territory inclusion as a foundational design requirement in any federal registry.

The FDA’s public docket for this hearing remains open at regulations.gov (Docket No. FDA-2026-N-7542) through October 5, 2026. The agency indicated that written comments, alongside testimony from the hearing, will inform continued federal coordination across FDA, VA, SAMHSA, NIDA, and ARPA-H.